Medtronic Announces Global Drug-Eluting Balloon Study

In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. MDT announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral™ drug-eluting balloon. The purpose of this prospective, multicenter study is to collect and assess safety and efficacy data on the Medtronic IN.PACT Admiral drug-eluting balloon for the treatment of atherosclerotic disease in the superficial femoral and/or popliteal arteries. This study calls for enrolling up to 1,500 “real world” patients at up to 80 sites in numerous countries and will allow lesions of any length. Steering committee members for the Medtronic IN.PACT Global SFA clinical study thus far include Drs. Gunnar Tepe (Germany), Marc Bosiers (Belgium), Do Dai Do (Switzerland), Peter Gaines (UK), Alvaro Razuk (Brazil) and Gary Ansel